UCB Group Transfers Back To Recordati S.p.A The Rights For The Sale Of Corifeo(R) (Lercanidipine) In Germany

UCB announces that it has reached an agreement with Recordati to transfer back the sales and marketing rights in Germany of Corifeo®, an antihypertensive calcium channel blocker, for a payment to UCB of 10 million euros.